Extended Data Fig. 2: Mcu Δmye mice show no change in global immune cell populations or activation phenotype at naïve status.
Supplementary Figure 2. Mcu Δmye mice show no change in global immune cell populations or activation phenotype at naïve status. a, Cartoon of the strategy to generate myeloid-specific Mcu deletion mice and the primers used for genotyping. b, Genotyping result for indicated mice. c, Immunoblotting of MCU in Mcu fl/fl and Mcu Δmye mice. d, Gating strategy to determine the percentage of differentiated macrophages (CD11b+F4/80+) and B cells (CD19+) from peritoneal cavity of Mcu fl/fl and Mcu Δmye mice. e, The percentage of differentiated macrophages and B cells was shown. f, Gating strategy to determine the percentage of activated macrophage (CD80+, CD86+, MHCII+ and CD206+) from peritoneal cavity of Mcu fl/fl and Mcu Δmye mice. g, Quantification of the mean fluorescence intensity (MFI) of the activated macrophages. h, Gating strategy to determine the percentage of macrophages (CD11b+F4/80+), neutrophils (CD11b+Ly6G+), monocytes (CD11b+Ly6C+) and conventional dendritic cells (CD11b+CD11c+) from spleen of Mcu fl/fl and Mcu Δmye mice. i, The percentage of macrophages, neutrophils, monocytes and dendritic cells was shown. j, Gating strategy to determine the percentage of B cells (CD19+) and T cells (CD3+CD4+ and CD3+CD8+) from spleen of Mcu fl/fl and Mcu Δmye mice. k and l, The percentage of B cells (k), and T cells (l) was shown. The averages of n = 3 biologically independent samples are shown. The error bars represent the SEM. Statistical significance was determined using t test (and nonparametric tests).
